Sarah Fredriksson has a master’s degree in biotechnology and is currently CEO of the biotech company Edvince AB, Lund. With a PhD from Lund University, Sarah founded the biotech company Genovis AB, which later went public. Sarah led the business as CEO until 2015. Sarah is also involved in the industry through various board assignments in Life Science and as a business developer at SmiLe incubator in Lund. She has a strong personal interest in innovation and entrepreneurship in pharmaceuticals, biotechnology and medical devices.
– “We are very pleased to have been able to bring Sarah Fredriksson’s significant experience, expertise and leadership to PULS to implement the company’s strategic direction and focus on an increased portfolio of innovative projects,” comments Ragnar Lindqvist, Chairman of the Board of PULS.
– Drug development is highly driven by regulatory requirements and therefore relatively predetermined, which is why the early phase of projects is the most exciting. Then a strategic analysis by an experienced team can make a big difference to the future of the project from idea to patient. PULS has chosen a very interesting position in the market and has done very well with the projects it has taken on so far with good opportunities for successful exits. “I am delighted to be entrusted with leading PULS together with a knowledgeable and successful team and the members of PULS’ unique partnership,” comments Sarah Fredriksson.
The company’s current CEO, Pontus Ottosson, will leave PULS at the end of April/May to take up another position in his home town of Gothenburg.
– It has been inspiring to help build PULS into a well-established and leading player in Life Science. With the breadth and depth of expertise within the PULS partnership, it has been a pleasure to work with all the talented and committed people. After 13 years, it is time for me to move on to new challenges in my local area,” says Pontus Ottosson.
– During his years at PULS, Pontus Ottosson has strongly contributed to the company’s current position as a significant player in the development and commercialization of product ideas in Life Science. We would like to thank Pontus and wish him good luck with his future tasks,” concludes Ragnar Lindqvist.
Board of Directors
For more information, please contact
Ragnar Lindqvist, Chairman of the Board, 0709-777 217
Sarah Fredriksson, incoming CEO, 0702-614 575
Pontus Ottosson, outgoing CEO, 0705-359 334